Compare Cytokinetics Inc (CYTK) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs TJX Companies Inc — how do they compare? Cytokinetics Inc trades at $62.69 (market cap $8.62B), while TJX Companies Inc trades at $138.86 (market cap $152.62B). The key difference: TJX Companies Inc is far larger — about 17.7× Cytokinetics Inc's market cap, and TJX Companies Inc pays a 1.38% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and TJX Companies Inc for 97 Days on average.
| CYTK | TJX | |
|---|---|---|
Market Cap | $8.62B | $152.62B |
Volume | 2,594,626 | 8,079,794 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $168.41 |
52-Week Low | $54.76 | $122.84 |
Typical Hold Time | 19 Days | 97 Days |
Enterprise Value | $8.72B | $160.93B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
TJX trades at $138.70, down slightly by 0.07% on the day, with a bullish technical signal from moving averages but overbought RSI readings near 75. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue and net income have grown steadily, reaching $56.36 billion and $4.86 billion in 2025, respectively, while maintaining a robust ROE of 62.17%.
Wall Street analysts are overwhelmingly bullish, with an 84.9% buy rating and a consensus price target of $174.15, implying 28% upside. Key risks include competitive pressures in off-price retail and potential macroeconomic headwinds affecting consumer spending. The stock's valuation at a P/E of 25.69 appears justified by its earnings growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
